WHAT IS CLAIMED IS:

1. A composition of subunit dengue vaccine, comprising:

a fusion protein of a delta-C nonstructural protein 1 (NS1ΔC) polypeptide conjugating or connecting to at least one polypeptides of a NS3c polypeptide and/or a consensus envelope protein domain III (cEDIII) polypeptide, wherein the NS1ΔC polypeptide is listed as SEQ ID NOs: 2 or 5, the cEDIII polypeptide is listed as SEQ ID NOs: 1 or 4, and the NS3c polypeptide is listed as SEQ ID NOs: 3 or 6; and

optionally together with one or more pharmaceutically acceptable carriers and/or adjuvants.

2. A composition of subunit dengue vaccine, comprising:

a fusion protein including a cEDIII polypeptide and a NS1ΔC polypeptide, wherein the cEDIII polypeptide is listed as SEQ ID NOs: 1 or 4, the NS1ΔC polypeptide is listed as SEQ ID NOs: 2 or 5;

a NS3c polypeptide including SEQ ID NOs: 3 or 6; and

optionally together with one or more pharmaceutically acceptable carriers and/or adjuvants.

3. The composition according to claim 2, wherein the fusion protein is in

~~an order of cEDIII-NS1ΔC from N-terminus to C-terminus.~~

~~4. The composition according to claim 3, wherein the fusion protein includes a first linker between the cEDIII polypeptide and the NS1ΔC polypeptide.~~

~~5. The composition according to claim 3, wherein the fusion protein is conjugated to the NS3c polypeptide.~~

~~6. The composition according to claim 5, wherein a second linker is conjugated to between the NS1ΔC polypeptide and the NS3c polypeptide.~~

~~7. The composition according to claim 2, wherein the fusion protein is in an order of NS1ΔC-cEDIII from N-terminus to C-terminus.~~

~~8. The composition according to claim 7, wherein the fusion protein includes a first linker between the cEDIII polypeptide and the NS1ΔC polypeptide.~~

~~9. The composition according to claim 7, wherein the fusion protein is conjugated to the NS3c polypeptide.~~

~~10. The composition according to claim 9, wherein a second linker is~~

~~conjugated to between the cEDIII polypeptide and the NS3c polypeptide.~~

~~11~~1. A composition of subunit dengue vaccine, comprising:

a fusion protein of truncated NS1 polypeptide consisting of SEQ ID NOs: 5 and truncated NS3c polypeptide consisting of SEQ ID NOs: 6, and optionally together with one or more pharmaceutically acceptable carriers and/or adjuvants.

~~12. The composition according to claim 11, wherein the fusion protein is in an order of truncated NS1-truncated NS3c from N-terminus to C-terminus.~~

~~13. The composition according to claim 12, wherein the fusion protein includes a first linker between the truncated NS1 and the truncated NS3c polypeptide.~~

~~14. The composition according to claim 11, wherein the fusion protein is in an order of truncated NS3c-truncated NS1 from N-terminus to C-terminus.~~

~~15. The composition according to claim 14, wherein the fusion protein includes a first linker between the truncated NS1 polypeptide and the truncated NS3c polypeptide.~~

~~16~~2. The composition according to claim ~~11~~1, further comprising a cEDIII polypeptide ~~listed as~~consisting of SEQ ID NOs: 1 or 4.

~~17. The composition according to claim 16, wherein the truncated NS1 polypeptide of the fusion protein is conjugated to the cEDIII polypeptide.~~

~~18. The composition according to claim 16, wherein the truncated NS3c polypeptide of the fusion protein is conjugated to the cEDIII polypeptide.~~

~~19. The composition according to claim 16, wherein the cEDIII polypeptide is conjugated between the truncated NS1 polypeptide and the truncated NS3c polypeptide.~~

3. A use of a fusion protein in the manufacture of a medicament for reducing DENV-induced prolonged bleeding time, wherein the fusion protein is consisted of truncated NS1 polypeptide of SEQ ID NOs: 5 and truncated NS3c polypeptide of SEQ ID NOs: 6 in an order of truncated NS1-truncated NS3c from N-terminus to C-terminus.

4. A use of a fusion protein in the manufacture of a medicament for reducing DENV-induced prolonged bleeding time, wherein the fusion protein is consisted of truncated NS1 polypeptide consisting of SEQ ID NOs: 5, cEDIII

polypeptide consisting of SEQ ID NOs: 1 or 4, and truncated NS3c polypeptide consisting of SEQ ID NOs: 6 in an order of truncated NS1-cEDIII-truncated NS3c from N-terminus to C-terminus.